A virtual reality system provides effective exposure treatment for psychiatric patients suffering from a particular anxiety disorder.
The invention relates to the use of esuprone in the treatment of anxiety and anxiety-like states.
The device is useful for the treatment of depression anxiety or psychosis related disorders.
The device is useful for the treatment of depression, anxiety or psychosis related disorders.
The formulations described above comprising baicalin as the substantial component show excellent effect of antianxiety.
A computer system for reorienting, reducing anxiety, and/or reducing delirium risk of a patient in a hospital is provided.
One aspect of the present disclosure relates to a closed-loop therapy system for treating an anxiety or anxiety-associated disorder in a subject.
The purpose of the present invention is to increase consumer trust on commercial goods and enable consumers to select commercial goods without anxiety.
These compounds show a strong antianxiety effect on mammals, and are useful for prophylaxis and treatment of, for example, psychosomatic disease and anxiety neurosis.
It is confirmed that when the oral dose for mouse is in the range of 7.5-30mg/kg, baicalin shows significant effect of antianxiety.
Urocortin null mutant mice are hypersensitive to stress and display heightened anxiety-like behaviors in the elevated plus maze and open field tests.
These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.
Disclosed is a process for producing a mineral drinking water that is safe on health and is drinkable without anxiety.